New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials

The study found faster, less expensive, and more engaging trials can be achieved using tech-enabled decentralized clinical trial models

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.

With one of the first fact-based examinations of the return on investment of DCTs, IQVIA offers tangible data that can help sponsors calculate the overall benefit of building clinical trials around a decentralized model. DCT models can include a range of elements such as IQVIA’s (DCT) Platform and support services, research nursing & phlebotomy solutions, direct-to-patient recruitment, risk-based monitoring, electronic clinical outcomes assessments and e-diaries that allow patients to record data remotely.

In this analysis decentralized trials were assessed against 14 metrics across three categories – productivity, quality, and trial delivery, to determine how a DCT approach compared to traditional study models. The analysis found that sponsors can achieve faster, less expensive, and more engaging trials using DCT driven protocols. Specifically, the findings show substantial reductions in timelines for Final Protocol to First Patient In (FPI), timelines for FPI to Last Patient In, Screen Failure Rate, as well as protocol deviations. The analysis highlights that, while different trials experienced varying levels of benefits from a DCT approach, making decentralized models part of a clinical research strategy from the outset can lead to significant returns.

“DCTs deliver real value for patients, sites and sponsors,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “How you deploy your DCT model will determine the benefits delivered, ranging from improvements in patient recruitment and participation to higher quality data.”

Click here to read the white paper “DCTs Deliver Big ROI.” To learn more about IQVIA’s DCT platform and services, please visit iqvia.com/decentralized-trials.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005113/en/